Welcome to our dedicated page for Ovation news (Ticker: OVATF), a resource for investors and traders seeking the latest updates and insights on Ovation stock.
Ovation Science Inc. (OVATF) regularly issues news updates that highlight its progress in topical and transdermal cannabinoid products, Invisicare skin delivery technology and licensing partnerships. Company news often covers new licensing agreements in U.S. states and Canada, product launches with multi-state cannabis operators, and developments in its intellectual property portfolio, including patents for cannabinoid transdermal delivery.
Investors and industry observers following OVATF news can read about exclusive agreements with partners such as Planet 13 in Nevada and Florida, PA Options for Wellness in Pennsylvania, MidWest Roots in Missouri and Ripco Processing in Canada. Releases describe how these partners manufacture, market and distribute Ovation’s formulations in regulated markets, and how Ovation earns royalties based on sales. Updates also discuss the performance of Ovation’s topicals in laboratory testing and their positioning within medical, wellness and beauty categories.
Ovation’s news flow also features strategic collaborations, including its enhanced partnership with Skinvisible Pharmaceuticals to apply Invisicare technology and cannabinoid formulations in areas such as obesity and metabolic health. Regulatory context, such as U.S. cannabis rescheduling, is frequently discussed in terms of potential opportunities for science-based topical products and licensing expansion.
This OVATF news page aggregates press releases and announcements so readers can track licensing milestones, product rollouts, patent activity and strategic initiatives related to Ovation’s Invisicare-powered cannabinoid topicals. For those monitoring the company’s evolution within the cannabis and wellness ecosystem, it provides a centralized view of key corporate developments over time.
Ovation Science (OTC:OVATF) announced issuance of a new Canadian patent for proprietary topical formulations delivering CBD and THC, expanding protection beyond its existing U.S. patent and strengthening its international IP portfolio.
The patent covers formulations using Ovation's Invisicare transdermal technology, which the company says delivered CBD bioavailability of up to 82% in lab comparisons versus 2–3% for competing transdermals and ~6% for oral gummies. Ovation reports four licensees and positions the patent to support licensing, partnerships, and commercialization in regulated markets in 2026.
Ovation Science (OTC PINK:OVATF) says U.S. cannabis rescheduling expands opportunities for its science-based topical and transdermal cannabinoid products, especially THC-free CBD topicals designed for potential Medicare eligibility.
The company cites its patented Invisicare® delivery platform and comparative lab results showing 82% CBD bioavailability versus 2–3% for competing topicals and ~6% for oral CBD. Ovation notes licensing activity in four states, royalty and product sales revenue models, and a potential addressable Medicare population of ~68 million beneficiaries with an estimated 35% experiencing inflammation-related conditions.
Ovation Science (OTC:OVATF) has strengthened its strategic partnership with Skinvisible Pharmaceuticals to develop innovative cannabinoid-based solutions for the obesity market, leveraging the patent-pending Invisicare® delivery technology. The enhanced collaboration maintains Ovation's exclusive worldwide rights to manufacture and distribute products using Skinvisible's technology.
The partnership focuses on THC-V (tetrahydrocannabivarin), showing promise as an appetite suppressant and metabolic function enhancer without psychoactive effects. The transdermal delivery system aims to reduce gastrointestinal side effects common in obesity treatments. This positions both companies to target the global obesity therapy market, projected to reach $150 billion by 2035.
Ovation Science (OTC:OVATF) has expanded its license agreement with Planet 13 Holdings to bring its patented Invisicare® topical and transdermal cannabis products to the Florida market. The products will be distributed across Planet 13's network of 33 Florida dispensaries, building on their successful collaboration in Nevada.
Florida represents a significant opportunity as the largest medical cannabis market in the US, projected to exceed $2.5 billion in cannabis sales in 2025. The state has almost one million registered patients and leads in topical sales nationwide. Ovation's Invisicare® technology demonstrates superior bioavailability with 82% cannabinoid penetration compared to less than 2% for competitors.
This expansion marks Ovation's third active market, alongside Nevada and Pennsylvania, with additional planned expansions in Missouri and Canada. The company will earn royalty income from Planet 13's sales in both Nevada and Florida under this expanded agreement.
Ovation Science announces the launch of its patented transdermal cannabis products in Pennsylvania through licensee PA Options for Wellness. This marks Ovation's second US licensee, targeting a market with over 850,000 registered patients and caregivers across 170+ dispensaries. PA Options, operating six dispensaries under Vytal Options brand with 32,000 registered medical patients, will distribute Ovation's products under the 'Mood' brand.
The company's formulations utilize Invisicare® technology, showing 10 times greater CBD release through the skin compared to other tested products. Ovation is expanding its US presence, with ongoing operations in Nevada through Planet 13 and planned entry into Missouri via MidWest Roots in January 2025. The company has terminated its licensing agreement with Stash House Distribution for Oklahoma, New Mexico, and Mississippi.
Ovation Science Inc. announced the launch of its topical product line in Nevada with Planet 13 Holdings, Inc., featuring both cannabis and hemp-derived products. The partnership aims to expand brand presence and generate revenue for both companies. Ovation's proprietary skin delivery technology, Invisicare®, enhances product effectiveness, with significant CBD release compared to competitors. Planet 13's topicals include various ratios of CBD and THC for relaxation, relief, and recovery. The companies are optimistic about driving growth and optimizing gross margins through this collaboration.
Summary not available.
Summary not available.
Summary not available.
Summary not available.